Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.
about
Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatmentA systematic review of the effects of low-frequency repetitive transcranial magnetic stimulation on cognitionLifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort.Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.Factors associated with non evidence-based prescribing of antipsychoticsRelationship of neurocognitive deficits to diagnosis and symptoms across affective and non-affective psychoses.Cognitive impairment in patients with a schizoaffective disorder: a comparison with bipolar patients in euthymia.Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.Safety and tolerability of antipsychotic polypharmacy.Clarifying delirium management: practical, evidenced-based, expert recommendations for clinical practiceInfluence of Antipsychotic and Anticholinergic Loads on Cognitive Functions in Patients with Schizophrenia.Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practiceLong-term antipsychotic polypharmacy: how does it start, why does it continue?Comparing the influences of age and disease on the Brief Assessment of Cognition in Schizophrenia in Japanese patients with schizophrenia.Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study.Antipsychotic polypharmacy in schizophrenia: benefits and risks.Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness.Treating the violent patient with psychosis or impulsivity utilizing antipsychotic polypharmacy and high-dose monotherapy.Correlation between age and MMSE in schizophrenia.Verbal learning and memory and their associations with brain morphology and illness course in schizophrenia spectrum psychoses.Comparison of treatment patterns in schizophrenia between China and Japan (2001-2009).Prevalence of and factors associated with antipsychotic polypharmacy in patients with serious mental illness: Findings from a cross-sectional study in an upper-middle-income country.Multitarget drug discovery projects in CNS diseases: quantitative systems pharmacology as a possible path forward.Clozapine and visuospatial processing in treatment-resistant schizophrenia.Pharmacokinetic patterns of risperidone-associated adverse drug reactions.Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia.Omega-3 fatty acids related to cognitive impairment in patients with schizophrenia.Reducing antipsychotic polypharmacy among psychogeriatric and adult patients with chronic schizophrenia.Antipsychotic medications: linking receptor antagonism to neuropsychological functioning in first episode psychosis.Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: findings of the third national survey on use of psychotropic medications in China.Is cognitive impairment associated with antipsychotic dose and anticholinergic equivalent loads in first-episode psychosis?Association between using medications with anticholinergic properties and short-term cognitive decline among older men: A retrospective cohort study in Taiwan.Serum levels of second-generation antipsychotics are associated with cognitive function in psychotic disorders.Deconstructing violence as a medical syndrome: mapping psychotic, impulsive, and predatory subtypes to malfunctioning brain circuits.Preliminary investigation of the effects of γ-tACS on working memory in schizophrenia.Potential neuroprotective effect of lithium in bipolar patients evaluated by neuropsychological assessment: preliminary results.Neuropsychological and functional correlates of clock-drawing test in elderly institutionalized patients with schizophrenia.General and domain-specific neurocognitive impairments in deficit and non-deficit schizophrenia.Effects of anticholinergic challenge on psychopathology and cognition in drug-free patients with schizophrenia and healthy volunteers.The Impact of Aging, Psychotic Symptoms, Medication, and Brain-Derived Neurotrophic Factor on Cognitive Impairment in Japanese Chronic Schizophrenia Patients.
P2860
Q27028197-F8E02972-4827-45B8-8921-35971671C356Q28079632-4B474ED9-9F3D-43E3-BD74-D38FAC4ADD8EQ30835228-6491CF37-F8FF-4059-9D15-6C60054D9A9AQ34145251-B3730352-0B77-4FC3-92FF-88630A8359FBQ34642808-44901B78-2576-4C3A-9C51-54501C94BFA5Q35577541-3D48D344-5DB8-424E-9A1B-6DC4854AA102Q35959392-613FF71A-520F-4170-99EF-DEC3BB976A73Q36057820-F118AFA9-7D9C-4EC8-8E8C-E4140E0F3BCEQ36062421-61961B5D-346F-449A-AA88-6BCCDA67BE97Q36728558-3BA3C800-5CD8-4EED-A523-85A8F24E63A2Q36828285-46227B0B-A4BD-4E2A-B255-54BCBB1C3407Q37029622-9F397734-D217-432F-9ECD-A5CD86368CC8Q37079008-ADCAC3A1-00EE-4D30-A3D0-17E4D746E27DQ37106851-CFF542F6-C2B1-4C46-A845-52731AF065FBQ37131080-85A5F6EE-20A6-42DF-A0AC-6ADA48FF09B9Q37863093-512DD970-01BC-49DA-8ED7-6C9EF57B7C23Q38081872-DAB1F871-A303-4B04-B7AF-D17EC747D578Q38239613-02380DE8-EDA6-4CB8-A947-36C9B4023547Q38420511-9C6BA0DF-6F44-4526-8ADC-314AE21A3083Q38473103-5BB0D292-4A85-494F-9EB5-D5698E5375CAQ38950803-4DD74E30-7B4A-49F1-8663-569841C95D90Q38972585-B690EC4B-8724-41E3-BE96-28C5F4AF4DDEQ39062177-BC9B4516-1E3D-4156-BD3C-C210E932ECCFQ39480375-B4468E36-AEED-49B3-9AD4-E4C3994633E4Q39633628-AEFAE9EF-5914-4C52-889B-6D87BE104BE2Q40626667-6F91B437-F634-41F2-AA0F-7E9170EE6E88Q41040716-ED375576-1D9F-48E5-A5F0-2EACE3C10F56Q42835527-A9F06F69-844F-43E8-A034-D0F4A84221D4Q44504730-E0A86963-13A7-4E3B-9611-B91A0A9EECD3Q44897335-74FFA331-0A1C-4E4C-81D3-42216C026F1DQ47556225-9E3669B2-5CE0-4718-83DE-8A491081619EQ47741746-B626502A-492F-447A-9C7A-D6F785D57673Q47920400-6812ACAF-5C74-41E4-9226-921BF55C34D9Q48492684-9762AB15-DEAB-461D-861B-B78E64BEF869Q48792541-05AB23DA-E0FD-4964-B6D5-38344CD25BF1Q50549737-04CC1384-44A7-4CC0-BB1B-9566B6A356C9Q50729635-2B812E7D-9AF6-4F88-8952-482CB67BA66FQ50998462-AA15BE22-BDAD-4B3C-995B-585C43982D39Q52654822-BB187874-B963-497E-8F4A-E555E7B4566DQ55285594-D197E783-11A3-4305-9969-E9142184D16B
P2860
Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Cognitive effects of antipsych ...... and schizoaffective disorder.
@ast
Cognitive effects of antipsych ...... and schizoaffective disorder.
@en
Cognitive effects of antipsych ...... and schizoaffective disorder.
@nl
type
label
Cognitive effects of antipsych ...... and schizoaffective disorder.
@ast
Cognitive effects of antipsych ...... and schizoaffective disorder.
@en
Cognitive effects of antipsych ...... and schizoaffective disorder.
@nl
prefLabel
Cognitive effects of antipsych ...... and schizoaffective disorder.
@ast
Cognitive effects of antipsych ...... and schizoaffective disorder.
@en
Cognitive effects of antipsych ...... and schizoaffective disorder.
@nl
P2093
P2860
P356
P1476
Cognitive effects of antipsych ...... and schizoaffective disorder.
@en
P2093
P2860
P304
P356
10.1177/0269881108100777
P407
P577
2009-01-22T00:00:00Z